Citations

Clear

40 citation(s) found for "Sinclair, Rd".

Decision stability among adolescents and young adults making choices about learning genomic research results
Blumling, Amy A. , Elder, Holly , Sinclair, Jessica , Mulukutla, Srimayi, Mahoney, Madeline , Prows, Cynthia A. , Myers, Melanie F. , McGowan, Michelle L. , Sinclair, Jessica A, Myers, Melanie F , Mahoney, Madeline

Mayo Clinic

Journal of Genetic Counseling | April 4, 2025 | Volume: 34 | Issue: 2 | Pages: No page available

10.1002/jgc4.2010 | PMID 40176371 Get It

AbstractWith increasing opportunities for minors to undergo genomic testing, factors influencing young people's decision stability and instability regarding genomic testing are unclear. This interpretive description study examines decision stability when adolescents (13–17) and young adults (18–21) decide whether to learn genetic testing results. Adolescents and young adults enrolled in a clinical trial chose whether they wanted to learn genetic testing results and could modify their decisions during a study visit or 2 weeks later. A purposive sample of clinical trial participants was invited to participate in an interview exploring their decision preferences, confidence level, and factors impacting decision stability. Twenty‐two participants chose to learn all (n = 7), some (n = 7), or no genetic test results (n = 8). Perceptions of the impact of personal genetic information on one's quality of life and sense of reproductive goals and responsibilities were driving factors for people who chose to learn no or some genetic results, while curiosity influenced those who chose to learn all. Prior health and healthcare experiences and others' influence also factored into decision‐making about receiving results. Decision stability varied among individuals but increased over time and was positively influenced by parents, baseline decision confidence, and fear of missing out on the opportunity to learn genetic information. Participants felt favorably about the opportunity to change their decision 2 weeks after the study visit. Among study participants, decision stability was high, as was satisfaction with decisions regarding how much personal genetic information to learn. The results suggest that adolescent and young adult genetic research participants may experience high decision stability and confidence in making choices regarding personal genetic testing, especially when a window of opportunity for change is available. Researchers and clinicians should consider the benefits and challenges of offering multiple checkpoints to bolster decision stability.
1631: ASSOCIATION OF INDUCTION AGENTS FOR INTUBATION AND OUTCOMES IN SEPSIS: A TARGET TRIAL EMULATION
Bhavsar, Vatsa, Khanijo, Aditya , Anes, Joguncic, KC, Anil, Rodriguez, Allison Perez, FRÍAS, JORGE SINCLAIR DE , Cureton, Kimberly D., Robbins, Kellie, Reddy, Swetha , Lal, Amos , Kashani, Kianoush , Franco, Pablo Moreno , Ghosh, Saptarshi , Menser, Terri

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001105188.86464.c3 Get It

Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity
Lyu, Yu-Xuan, Wilczok, Dominika , Antebi, Adam , Vojta, Aleksandar , Stolzing, Alexandra , Moskalev, Alexey , Georgievskaya, Anastasia , Maier, Andrea B. , Olsen, Andrea, Groth, Anja , Brunet, Anne , Jamil, Aisyah, Kulaga, Anton , Bhatti, A.R., Yaden, Benjamin C., Djordjevic, Boris, Chen, Chieh, Huang, Christine Yuan, Chen, Danica , Sołdacki, Dariusz, Meyer, David H. , Chini, Eduardo N. , Morgen, Eric , Vernet, Erik , Pinilla, Estefano, Mercken, Evi M. , Finger, Fabian , Kuipers, Folkert , Gyülvészi, Gábor, Zmudze, Garri, Blander, Gil , Pincus, Harold A., McClure, Joshua, Kirkland, James L. , Peyer, James , McLaughlin, Jerry L., Mannick, Joan B. , Betts-LaCroix, Joe , Sedivy, John M. , Speakman, John R. , Shlain, Jordan, Maltzahn, Julia von , Andreasson, Katrin I. , Moody, Kelsey , Fortney, Kristen , Niedernhofer, Laura J., Veenhoff, Liesbeth M. , Melton, Lisa , Quarta, Marco , Koval, Maria, Marinova, Maria B., Hamalainen, Mark, Unfried, Maximilian , Ringel, Michael S. , Filipović, Miloš R. , Topors, Mourad, Mitin, Natalia , Roy, N. N., Pintar, Nika, Barzilai, Nir , Binetti, Paolo, Kohlhaas, Paul, Rubin, Paul , Kamya, Petrina, Muñoz‐Cánoves, Pura , Конрад, Р. , Ripa, Roberto , Mansukhani, Robin, Büttner, Sabrina , Brunemeier, Sebastian, Jakimov, Sergey, Rosenzweig‐Lipson, Sharon, Tsai, Shih‐Yin , Rando, Thomas A. , Peterson, Timothy R. , Woods, Tina , Wyss‐Coray, Tony , Finkel, Toren , Strauss, Tzipora , Longo, Valter D. , Sorrentino, Vincenzo , Sebastiano, Vittorio , Li, Wenbin , Suh, Yousin , Niedernhofer, Laura J. , Lu, Yuxuan , Passos, Joao, Niedernhofer, Laura J , Wyss-Coray, Tony , Bakula, Daniela , Lyu, Yu-Xuan, Fu, Qiang , Ying, Kejun , King, Aaron, Olsen, Andrea, Simon, Anna Katharina , Jamil, Aisyah, Bhatti, Asif, Pedersen, Bente Klarlund , Schumacher, Björn , Kennedy, Brian Keith , Huang, Christine Yuan, Correll, Christoph Ulrich , Murphy, Coleen Tara , Ewald, Collin Y. , Valenzano, Dario Riccardo , Erritzøe, David , Sinclair, David , Teeling, Emma C. , Verdin, Eric , Pinilla, Estéfano , Fang, Evandro Fei , Bischof, Evelyne Y. , Pun, Frank W. , Civiletto, Gabriele , Justice, Jamie N. , Vijg, Jan , Gruhn, Jennifer R. , McLaughlin, Jerry, Passos, João F. , Baur, Joseph A. , Shlain, Jordan, Palikaras, Konstantinos , Rasmussen, Lene Juel , Ferrucci, Luigi , Koval, Maria, Topors, Mourad, Roy, Nawal, Pintar, Nika , Singh, Parminder Pal , Robbins, Paul D. , Fedichev, Peter O. , Cabo, Rafael de , Faragher, Richard , Konrad, Rob, Wickström, Sara A. , Brunemeier, Sebastian A., Luo, Shan , Dimmeler, Stefanie , Gladyshev, Vadim N. , Dwaraka, Varun B. , Gorbunova, Vera , Acosta-Rodríguez, Victoria A. , Suh, Yousin , Zhavoronkov, Alex , Scheibye‐Knudsen, Morten

Mayo Clinic

Aging | October 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.18632/aging.206135 | PMID 39418098 Get It

Rethinking Measures and Mortality Attribution in Health Care: The ENT Example
Patel, Samip , Olivero, Lorenzo , FRÍAS, JORGE SINCLAIR DE , Anderson, Stephanie S., Pollock, Ben D., Lee, Marian D., Chirilă, Răzvan M. , Guru, Pramod , Pollock, Benjamin D. , Sinclair, Jorge Enrique , Guru, Pramod K , Taylor, Richard, Moreno Franco, Pablo , Patel, Samip N , Pollock, Benjamin D , Lee, Marian D., Murthy, Hemant S. , Taylor, Richard A. , Franco, Pablo Moreno , Menser, Terri

Mayo Clinic

Otolaryngology–Head and Neck Surgery | October 13, 2024 | Volume: 171 | Issue: 6 | Pages: 1925-1927

10.1002/ohn.1015 | PMID 39396155 Get It

AbstractNational performance metrics ultimately enhance patient decision‐making and promote meaningful improvements in health care delivery, which makes having valid and reliable measures essential. This study examined US News and World Report metrics from 2019 to 2012 and used electronic health record data, combined with detailed chart review across 3 in‐system hospitals, to assess the provision of care compared to the attribution of patients assigned to the ear, nose, and throat (ENT) mortality group. Of the initial 47 ENT‐attributed deaths, 23 of those were verified, dimensioning the mortality rate from 1.7% to just 0.8%. These results underscore the necessity of rethinking measures and mortality attribution methodologies to be more accurate. Current methods use Medicare Severity Diagnosis Related Group billing coding to map the attribution. We suggest transitioning away from specialty ranking approaches and towards a procedure and condition “rating” approach to ensure that these ranking types capture data about the provision of care within a given encounter.
Increased Risk and Unique Clinical Course of Patient Safety Indicator-3 Pressure Injuries Among COVID-19 Hospitalized Patients
Cowart, Jennifer B. , FRÍAS, JORGE SINCLAIR DE , Pollock, Benjamin D. , Knepper, Camille, Sammon, Nora, Jonna, Sadhana , Singh, Trisha, Bhakta, Shivang , Olivero, Lorenzo , Ochoa, Shari A. , Ramar, Kannan , Singh, Tarun D. , De Frías, Jorge Sinclair, Pollock, Benjamin D , Knepper, Camille, Singh, Trisha, Franco, Pablo Moreno

Mayo Clinic

Journal of Patient Safety | September 13, 2024 | Volume: 20 | Issue: 8 | Pages: e128-e134

10.1097/pts.0000000000001276 | PMID 39269226 Get It

Background The COVID-19 pandemic introduced unique challenges to healthcare systems, particularly in relation to patient safety and adverse events during hospitalization. There is limited understanding of COVID-19’s association with some patient safety indicators (PSIs). Objectives This study aimed to investigate the impact of COVID-19 infection on the rate of PSI-3 events and its implications on quality metrics. We compared PSI-3 event rates between COVID-19–infected and uninfected patients and examined the clinical characteristics of COVID-19 patients experiencing PSI-3 events. Methods This is a retrospective study at Mayo Clinic hospitals between January 2020 and February 2022, analyzing patients meeting PSI-3 denominator eligibility criteria. PSI-3 events were identified using AHRQ WinQI software. Patients were categorized based on COVID-19 status. Patient demographics, characteristics, and PSI-3 rates were compared. A case series analysis described clinical details of COVID-19 patients with PSI-3 events. Results Of 126,781 encounters meeting PSI-3 criteria, 8674 (6.8%) had acute COVID-19 infection. COVID-19–infected patients were older, more likely to be male, non-white, and had private insurance. PSI-3 rates were significantly higher in COVID-19 patients (0.21% versus 0.06%, P < 0.0001), even after risk adjustment (adjusted risk ratio, 3.24, P < 0.0001). The case series of 17 COVID-19 patients with PSI-3 events showed distinctive clinical characteristics, including higher medical device–related pressure injuries, and greater predisposition for head, face, and neck region. Conclusions Acute COVID-19 infection correlates with higher PSI-3 event rates. Current quality indicators may require adaptation to address the pandemic’s complexities and impact on patient safety. Further research is needed to comprehensively understand the intricate relationship between COVID-19 and patient outcomes.
Frailty predicts adverse outcomes in older patients with pulmonary embolism
FRÍAS, JORGE SINCLAIR DE , Olivero, Lorenzo , GABELA, ABIGAIL, Jaen, Diana, Franco, Pablo Moreno , Sinclair, Jorge Enrique , Moreno Franco, Pablo , Menser, Terri

Mayo Clinic

Geriatrics & Gerontology International | August 15, 2024 | Volume: 24 | Issue: 9 | Pages: 924-929

10.1111/ggi.14961 | PMID 39143935 Get It

Aim This study aims to evaluate the impact of frailty on the outcomes of older patients with pulmonary embolism (PE). Methods Using the National Inpatient Sample database, we identified 288 070 patients aged 65 or older who were admitted with a primary diagnosis of PE from 2017 to 2019. Frailty was assessed using the Hospital Frailty Risk Score (HFRS), and patients were categorized into low‐, intermediate‐, and high‐frailty‐risk groups. Multivariate logistic regression was used to calculate adjusted odds ratios for all outcomes. Results These patients were categorized into low‐risk (57.6%, 161 420), medium‐risk (39.9%, 111 805), and high‐risk (2.5%, 7075) groups. High‐risk patients, predominantly females with multiple comorbidities, exhibited significantly higher mortality rates and adverse outcomes. The HFRS showed a good discriminating ability in predicting mortality (area under the receiver operating characteristic curve = 0.7796). Frailty was associated with increased use of advanced therapeutic interventions and critical care resources such as thrombolysis, catheter‐directed therapies, inferior vena cava filter placement, mechanical ventilation, vasopressor use, and intensive care unit admission. Conclusion Frailty markedly affects outcomes in older PE patients. The HFRS offers a valuable prognostic tool in this population, suggesting that integrating frailty assessments into clinical practice could enhance care strategies and improve patient outcomes. Our findings underscore the need for further research to refine frailty‐based care paradigms. Geriatr Gerontol Int 2024; 24: 924–929 .
Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury
Ashina, Håkan , Diener, Hans‐Christoph , Tassorelli, Cristina , Lipton, Richard B. , Pozo‐Rosich, Patricia , Chong, Catherine D. , Finkel, Alan G. , Lipton, R.B. , Pozo-Rosich, Patricia , Chong, Catherine D , Diener, Hans-Christoph , Ashina, Håkan , Scher, I , Sinclair, Alexandra Jean , Ashina, Messoud , Schwedt, Todd J. , Dodick, David W. , Terwindt, Gisela M.

Mayo Clinic

Cephalalgia | March 22, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1177/03331024241234068 | PMID 38518177 Get It

Background Persistent headache attributed to traumatic injury to the head is divided into two subtypes, one attributed to moderate or severe traumatic injury and another attributed to mild traumatic injury (i.e., concussion). The latter is much more prevalent, in part because more than 90% of cases with traumatic brain injury are classified as mild. The pathophysiology of persistent post-traumatic headache is poorly understood and the underlying mechanisms are likely multifactorial. There is currently no approved treatment specifically for persistent post-traumatic headache, and management strategies rely on medications used for migraine or tension-type headache. Therefore, high-quality trials are urgently needed to support clinical decision-making and optimize management strategies. International guidelines can facilitate appropriate trial design and ensure the acquisition of high-quality data evaluating the efficacy, tolerability, and safety of available and novel pharmacological therapies for the preventive treatment of persistent post-traumatic headache. Methods The development of this guideline was based on a literature review of available studies in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, along with a review of previously published guidelines for controlled trials of preventive treatment for episodic and chronic migraine. The identified literature was critically appraised, and due to the scarcity of scientific evidence, recommendations were primarily based on the consensus of experts in the field. Objective To provide guidelines for designing state-of-the-art controlled clinical trials aimed at evaluating the effectiveness of preventive treatments for persistent post-traumatic headache attributed to mild traumatic brain injury.
Association Between Impella Device Support and Elevated Rates of Gout Flares: A Retrospective Analysis
Sinclair, Jorge , Raavi, Lekhya , Narra, Sai Abhishek, Paghdar, Smit , Jonna, Sadhana , SATASHIA, PARTHKUMAR , Hannon, Rachel, Blasavage, Jessica, White, L. O., Olanipekun, Titilope , Kiley, Sean , Leoni, Juan , Nativí, Jose, Lyle, Melissa , Sareyyüpoğlu, Başar , Patel, Parag, Sanghavi, Devang , Isha, Shahin , Olivero, Lorenzo , White, Layton, Bansal, Pankaj , Leoni, Juan Carlos , Thomas, Mathew , Pham, Si M. , Smith, Michael, Franco, Pablo Moreno

Mayo Clinic

No container title available | November 13, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3549951/v1 Get It

Abstract Background Impella is an advanced ventricular assist device frequently used as a bridge to heart transplantation. The association of Impella with increased rates of gout flares has not been studied. Our primary aim is to determine the rates of gout flares in patients on Impella support. Methodology A retrospective study was conducted between January 2017 and September 2022 involving all patients who underwent heart transplantation. The cohort was divided into groups based on Impella support for statistical analysis. In patients receiving Impella support, outcome measures were compared based on the development of gout flares. Results 213 patients were analyzed, with 19.71% supported by Impella. Impella and non-Impella groups had similar age, race, and BMI, but more males were in the Impella group. Gout and chronic kidney disease were more prevalent in Impella-supported patients, while coronary artery disease was less common. The incidence of gout flare was significantly higher in Impella patients (31% vs. 5.3%). The Impella group had an adjusted odds ratio for in-hospital gout flare of 8.069 (95% CI = 2.13–35.08, P = 0.003). Impella-supported patients with gout flares had longer intensive care unit and hospital stays but no difference in mortality or other outcomes. Conclusion Our study is the first to identify the potential association between Impella support and increased rates of gout flares in hospitalized patients. Future studies are required to confirm this association and further elucidate the biological pathways. It is imperative to consider introducing appropriate measures to prevent and promptly manage gout flares in Impella-supported patients.
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
Rinella, Mary E. , Lieu, Hsiao D., Goodman, Zachary , Alkhouri, Naim , Abdelmalek, Manal F. , Wong, Vincent Wai‐Sun , Younes, Ziad , Sheikh, Aasim , Brannan, Donald, Freilich, B., Membreno, Fernando E., Sinclair, Marie , Melchor‐Khan, Liza, Ling, Lei , Abdelmalek, Manal , Wong, Vincent Wai-Sun , Rinella, Mary , Kowdley, Kris V. , Lawitz, Eric , Ratziu, Vlad , Brannan, Donald, Sanyal, Arun J. , Harrison, Stephen A.

Mayo Clinic

Hepatology | September 21, 2023 | Volume: 79 | Issue: 3 | Pages: 674-689

10.1097/hep.0000000000000607 | PMID 37732990 Get It

Background and Aims: Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with noncirrhotic NASH; however, its efficacy and safety in compensated cirrhosis is unknown. No drug has yet to demonstrate benefit in the compensated NASH population. Approach and Results: In this multicenter, double-blind, placebo-controlled, phase 2b trial, 160 patients with compensated NASH cirrhosis were randomized to aldafermin 0.3 mg (n = 7), 1 mg (n = 42), 3 mg (n = 55), or placebo (n = 56) for 48 weeks. The 0.3 mg group was discontinued to limit exposure to suboptimal doses. The primary end point was a change in Enhanced Liver Fibrosis from baseline to week 48. The analyses were performed in the intention-to-treat population. At week 48, the least-squares mean difference in the change in Enhanced Liver Fibrosis was −0.5 (95% CI, −0.7 to −0.2; p = 0.0003) between the 3 mg group and the placebo group. 15%, 21%, and 23% of patients in the placebo, 1 mg, and 3 mg group, respectively, achieved fibrosis improvement ≥ 1 stage; and 13%, 16%, and 20% achieved fibrosis improvement ≥ 1 stage without NASH worsening. Improvement in alanine aminotransferase, aspartate aminotransferase, neoepitope-specific N-terminal pro-peptide of type III collagen, and liver stiffness favored aldefermin groups over placebo. Diarrhea was the most frequent adverse event, occurring at 26% and 40% in the 1 mg and 3 mg groups, respectively, compared to 18% in the placebo group. Overall, 0%, 2%, and 9% of patients in the placebo, 1 mg, and 3 mg group, respectively, discontinued due to treatment-related adverse events. Conclusions: Aldafermin 3 mg resulted in a significant reduction in Enhanced Liver Fibrosis in patients with compensated NASH cirrhosis.
Pneumothorax, pneumomediastinum, and subcutaneous emphysema in hospitalized COVID-19 patients: incidence, clinical characteristics, and outcomes
Baptista, Aleksandra Murawska , FRÍAS, JORGE SINCLAIR DE , Singh, Trisha, Vasudhar, Ananya, Guzzino, Jacob , Khalili, Waheed, Bansal, Vikas , Joyce, William J., Lewis, Patricia A., Sanghavi, Devang , Gavrancic, Tatjana , Singh, Tarun D. , Murawska Baptista, Aleksandra, Sinclair, Jorge Enrique , Bansal, Vikas , Singh, Trisha, Tekin, Aysun , Kashyap, Rahul , Lewis, Patricia A., Franco, Pablo Moreno

Mayo Clinic

Expert Review of Respiratory Medicine | September 7, 2023 | Volume: 17 | Issue: 8 | Pages: 727-733

10.1080/17476348.2023.2254689 | PMID 37675598 Get It